GSK PLC
GS71
Company Profile
Business description
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Contact
79 New Oxford Street
LondonWC1A 1DG
GBRT: +44 2080475000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
66,841
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.20 | 19.30 | 0.22% |
| CAC 40 | 8,203.43 | 4.14 | 0.05% |
| DAX 40 | 24,433.06 | 183.16 | -0.74% |
| Dow JONES (US) | 50,872.11 | 86.10 | 0.17% |
| FTSE 100 | 10,227.33 | 145.87 | -1.41% |
| HKSE | 24,281.32 | 284.58 | -1.16% |
| NASDAQ | 25,678.82 | 250.84 | -0.97% |
| Nikkei 225 | 64,681.39 | 735.24 | -1.12% |
| NZX 50 Index | 13,183.81 | 20.27 | -0.15% |
| S&P 500 | 7,386.65 | 19.08 | -0.26% |
| S&P/ASX 200 | 8,623.30 | 31.90 | 0.37% |
| SSE Composite Index | 3,979.09 | 30.94 | -0.77% |